Biocon News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Biocon from all sources in a single place.

Biocon Ltd.

13 Jan 2026, 04:54PM

377.30

1.48%

Board Meeting

Biocon Ltd - 532523 - Board Meeting Intimation for Intimation For The Board Meeting And Earnings …

BSE India

Biocon Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2026 ,inter alia, to consider and approve Intimation for the Board Meeting and Earnings Conference Call for Analysts and Investors

pdf

Biocon Ltd.

13 Jan 2026, 02:25PM

377.30

1.48%

Biocon QIP to ease balance sheet pressure; metals, PSU banks favoured in near term: Nischal Maheshwari

Economic Times

Biocon's fundraising is viewed positively to manage debt. Expert Nischal Maheshwari is optimistic about Biocon's future, expecting earlier investments to yield returns. He also favors contract development and manufacturing firms like Laurus Labs. Maheshwari sees potential in banking, metals, and power sectors, particularly execution-focused players in power.

Biocon Ltd. has an average target of 401.80 from 5 brokers.

Biocon Ltd.

12 Jan 2026, 08:57PM

377.30

1.48%

Biocon opens 4,500 crore QIP, sets floor price at 387.74 per share

Business Standard

Biocon has opened a 4,500-crore QIP and fixed a floor price of 387.74 per share. The company said it may offer a discount of up to 5% and will finalise pricing with lead managers

Biocon Ltd. is trading below its 30 day SMA of 389.2

Biocon Ltd.

12 Jan 2026, 04:47PM

377.30

1.48%

Company Update

Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Qualified Institutional Placement

BSE India

Qualified Institutional Placement - Issue Opening

pdf

Biocon Ltd.

12 Jan 2026, 04:08PM

377.30

1.48%

Company Update

Biocon Ltd - 532523 - Intimation Of Approval Of Unaudited Condensed Consolidated Interim Financial Statements

BSE India

Intimation of approval of Unaudited Condensed Consolidated Interim Financial Statements

pdf

Biocon Ltd.

12 Jan 2026, 03:24PM

377.30

1.48%

Biocon arm gets USFDA nod for generic Everolimus tablets

Business Line

The approval granted by the US Food and Drug Administration (USFDA) is for the Abbreviated New Drug Application (ANDA) for Everolimus tablets for oral suspension in 2 mg, 3 mg and 5 mg strengths